Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical features of AML patients according to DNMT3A R882 mutation status

From: Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients

Clinical features Total
(n = 870)
R882 wild-type
(n = 796)
R882 mutation
(n = 74)
P value
Agea, years 42 ± 15 41 ± 15 48 ± 11 6.64 × 10 −6
Age ≥ 60 years, n (%) 103 (11.84) 94 (11.81) 9 (12.16) 0.928
Male, n (%) 476 (54.71) 443 (55.65) 33 (44.59) 0.068
FAB classification, n (%)
 M2 445 (51.15) 428 (53.77) 17 (22.97) 3.99 × 10 −7
 M4 180 (20.69) 162 (20.35) 18 (24.32) 0.420
 M5 173 (19.89) 139 (17.46) 34 (45.95) 4.31 × 10 −9
 Other subtypes or undetermined 72 (8.28) 67 (8.42) 5 (6.76)  
Parameters at diagnosisa
 WBC count, ×109/L 39.19 ± 62.25 37.56 ± 62.48 56.72 ± 57.27 0.012
 RBC count, ×1012/L 2.32 ± 1.53 2.32 ± 1.58 2.25 ± 0.66 0.710
 Hemoglobin, g/L 73.48 ± 21.11 73.45 ± 21.50 73.82 ± 16.36 0.858
 Platelets count, ×109/L 58.21 ± 83.94 55.99 ± 84.15 82.71 ± 78.02 0.010
 Neutrophil count, ×109/L 12.69 ± 32.04 12.53 ± 32.67 14.45 ± 24.10 0.630
 LDH, U/L 555.17 ± 694.61 553.00 ± 713.95 578.29 ± 441.34 0.771
 Bone marrow blasts, % 64.23 ± 21.40 63.97 ± 21.50 67.08 ± 20.19 0.244
Risk stratificationsb, n (%) n = 759c n = 696 n = 63  
 Intermediate risk 384 (50.59) 355 (51.01) 29 (46.03)  
 Low risk 202 (26.61) 190 (27.30) 12 (19.05) 0.467d
 High risk 173 (22.79) 151(21.70) 22 (34.92) 0.051d
FLT3-ITD, n (%) n = 733c n = 670 N = 63  
 Negative 637 (86.90) 591 (88.21) 46 (73.02)  
 Positive 96 (13.10) 79 (11.79) 17 (26.98) 0.001
Karyotype, n (%) n = 789c n = 721 n = 68  
 Normal cytogenetics 479 (60.71) 425 (58.95) 54 (79.41)  
 Non-normal cytogenetics 310 (39.29) 296 (41.05) 14 (20.59) 0.001
HSCT, n (%) 161 (18.51) 151 (18.97) 10 (13.51) 0.248
  1. FAB classification French–Britain–American classification, WBC white blood cell, RBC red blood cell, LDH lactate dehydrogenase, HSCT hematopoietic stem cell transplantation
  2. Italic values indicate significance of P value (P < 0.05)
  3. aData are presented as mean ± standard deviation (SD) for continuous variable
  4. bRisk stratification based on NCCN guidelines version 1.2015 acute myeloid leukemia
  5. cNumber of patients was based on the available clinical information
  6. dIntermediate risk was served as a reference